Skip to main content
NCBI home page
Heart logoLink to Heart
. 1996 Sep;76(3):232–237. doi: 10.1136/hrt.76.3.232

Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment.

T Omland 1, A Aakvaag 1, H Vik-Mo 1
PMCID: PMC484512  PMID: 8868981

Abstract

OBJECTIVE: To determine the usefulness of measuring the cardiac natriuretic peptides, atrial natriuretic factor, N-terminal pro-atrial natriuretic factor, and brain natriuretic peptide, as screening tests for identifying patients with mild left ventricular impairment. DESIGN: Cross-sectional evaluation of the diagnostic accuracy of the cardiac natriuretic peptides. SETTING: Cardiac catheterisation unit, Norwegian central hospital. PATIENTS: A consecutive series of 254 patients undergoing diagnostic left-sided cardiac catheterisation. One hundred and twenty eight of these patients had a history of previous myocardial infarction. MAIN OUTCOME MEASURES: The presence of normal and impaired left ventricular function, as evaluated by logistic regression analysis and estimation of the area under the receiver operating characteristic (ROC) curve (an index of overall diagnostic accuracy). Ventricular function was assessed by the measurement of left ventricular end diastolic pressure and angiographically determined left ventricular ejection fraction. RESULTS: Logistic regression analysis showed that plasma brain natriuretic peptide was the best predictor of increased left ventricular end diastolic pressure (> or = 15 mm Hg) (P < 0.001), decreased left ventricular ejection fraction (< or = 45%) (P < 0.001), and the combination of left ventricular ejection fraction < or = 45% and left ventricular end diastolic pressure > or = 15 mm Hg (P < 0.001). The areas under the ROC function for the detection of left ventricular dysfunction were 0.789 for brain natriuretic peptide, 0.665 for atrial natriuretic factor, and 0.610 for N-terminal pro-atrial natriuretic factor. CONCLUSIONS: Plasma brain natriuretic peptide seemed to be a better indicator of left ventricular function than plasma atrial natriuretic factor or N-terminal pro-atrial natriuretic factor. However, the overall diagnostic accuracy of circulating atrial natriuretic factor, N-terminal pro-atrial natriuretic factor, and brain natriuretic peptide as indicators of normal and impaired ventricular function in an unselected group of patients with coronary heart disease and a high frequency of previous myocardial infarction was relatively modest.

Full text

PDF
232

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benedict C. R., Johnstone D. E., Weiner D. H., Bourassa M. G., Bittner V., Kay R., Kirlin P., Greenberg B., Kohn R. M., Nicklas J. M. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 1994 May;23(6):1410–1420. doi: 10.1016/0735-1097(94)90385-9. [DOI] [PubMed] [Google Scholar]
  2. Caidahl K., Hedner J., Hedner T. Atrial natriuretic peptide and catecholamines in peripheral blood as indicators of cardiac dysfunction in the general population. Clin Sci (Lond) 1988 Jun;74(6):587–594. doi: 10.1042/cs0740587. [DOI] [PubMed] [Google Scholar]
  3. Choy A. M., Darbar D., Lang C. C., Pringle T. H., McNeill G. P., Kennedy N. S., Struthers A. D. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J. 1994 Jul;72(1):16–22. doi: 10.1136/hrt.72.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davidson N. C., Coutie W. J., Struthers A. D. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. Circulation. 1995 Feb 15;91(4):1276–1277. [PubMed] [Google Scholar]
  5. Francis G. S., Benedict C., Johnstone D. E., Kirlin P. C., Nicklas J., Liang C. S., Kubo S. H., Rudin-Toretsky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724–1729. doi: 10.1161/01.cir.82.5.1724. [DOI] [PubMed] [Google Scholar]
  6. Hall C., Aaberge L., Stokke O. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. Circulation. 1995 Feb 1;91(3):911–911. [PubMed] [Google Scholar]
  7. Hall C., Rouleau J. L., Moyè L., de Champlain J., Bichet D., Klein M., Sussex B., Packer M., Rouleau J., Arnold M. O. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994 May;89(5):1934–1942. doi: 10.1161/01.cir.89.5.1934. [DOI] [PubMed] [Google Scholar]
  8. Haug C., Metzele A., Kochs M., Hombach V., Grünert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993 Jul;16(7):553–557. doi: 10.1002/clc.4960160708. [DOI] [PubMed] [Google Scholar]
  9. Kettunen R. V., Leppäluoto J., Jounela A., Vuolteenaho O. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. Am Heart J. 1994 Jun;127(6):1449–1455. doi: 10.1016/0002-8703(94)90369-7. [DOI] [PubMed] [Google Scholar]
  10. Lenfant C. NHLBI funding policies. Enhancing stability, predictability, and cost control. Circulation. 1994 Jul;90(1):1–1. doi: 10.1161/01.cir.90.1.1. [DOI] [PubMed] [Google Scholar]
  11. Lenfant C. NHLBI funding policies. Enhancing stability, predictability, and cost control. Circulation. 1994 Jul;90(1):1–1. doi: 10.1161/01.cir.90.1.1. [DOI] [PubMed] [Google Scholar]
  12. Lerman A., Gibbons R. J., Rodeheffer R. J., Bailey K. R., McKinley L. J., Heublein D. M., Burnett J. C., Jr Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993 May 1;341(8853):1105–1109. doi: 10.1016/0140-6736(93)93125-k. [DOI] [PubMed] [Google Scholar]
  13. Mathisen P., Hall C., Simonsen S. Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest. 1993 Feb;53(1):41–49. doi: 10.1080/00365519309092530. [DOI] [PubMed] [Google Scholar]
  14. Motwani J. G., McAlpine H., Kennedy N., Struthers A. D. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993 May 1;341(8853):1109–1113. doi: 10.1016/0140-6736(93)93126-l. [DOI] [PubMed] [Google Scholar]
  15. Omland T., Aarsland T., Aakvaag A., Lie R. T., Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol. 1993 Aug 1;72(3):255–259. doi: 10.1016/0002-9149(93)90669-4. [DOI] [PubMed] [Google Scholar]
  16. Omland T., Bonarjee V. V., Aakvaag A., Aarsland T., Dickstein K. The relationship between early plasma atrial natriuretic factor levels and exercise performance after myocardial infarction. Eur Heart J. 1993 Aug;14(8):1022–1026. doi: 10.1093/eurheartj/14.8.1022. [DOI] [PubMed] [Google Scholar]
  17. Omland T., Bonarjee V. V., Nilsen D. W., Sundsfjord J. A., Lie R. T., Thibault G., Dickstein K. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J. 1993 Nov;70(5):409–414. doi: 10.1136/hrt.70.5.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  19. Raine A. E., Erne P., Bürgisser E., Müller F. B., Bolli P., Burkart F., Bühler F. R. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986 Aug 28;315(9):533–537. doi: 10.1056/NEJM198608283150901. [DOI] [PubMed] [Google Scholar]
  20. Remes J., Miettinen H., Reunanen A., Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991 Mar;12(3):315–321. doi: 10.1093/oxfordjournals.eurheartj.a059896. [DOI] [PubMed] [Google Scholar]
  21. Richards A. M., Crozier I. G., Yandle T. G., Espiner E. A., Ikram H., Nicholls M. G. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J. 1993 May;69(5):414–417. doi: 10.1136/hrt.69.5.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rouleau J. L., Packer M., Moyé L., de Champlain J., Bichet D., Klein M., Rouleau J. R., Sussex B., Arnold J. M., Sestier F. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994 Sep;24(3):583–591. doi: 10.1016/0735-1097(94)90001-9. [DOI] [PubMed] [Google Scholar]
  23. Rouleau J. L., de Champlain J., Klein M., Bichet D., Moyé L., Packer M., Dagenais G. R., Sussex B., Arnold J. M., Sestier F. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 1993 Aug;22(2):390–398. doi: 10.1016/0735-1097(93)90042-y. [DOI] [PubMed] [Google Scholar]
  24. Sandler H., Dodge H. T. The use of single plane angiocardiograms for the calculation of left ventricular volume in man. Am Heart J. 1968 Mar;75(3):325–334. doi: 10.1016/0002-8703(68)90089-6. [DOI] [PubMed] [Google Scholar]
  25. Struthers A. D. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ. 1994 Jun 18;308(6944):1615–1619. doi: 10.1136/bmj.308.6944.1615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wallén T., Landahl S., Hedner T., Hedner J., Hall C. Atrial peptides, ANP(1-98) and ANP(99-126) in health and disease in an elderly population. Eur Heart J. 1993 Nov;14(11):1508–1513. doi: 10.1093/eurheartj/14.11.1508. [DOI] [PubMed] [Google Scholar]
  27. Wei C. M., Heublein D. M., Perrella M. A., Lerman A., Rodeheffer R. J., McGregor C. G., Edwards W. D., Schaff H. V., Burnett J. C., Jr Natriuretic peptide system in human heart failure. Circulation. 1993 Sep;88(3):1004–1009. doi: 10.1161/01.cir.88.3.1004. [DOI] [PubMed] [Google Scholar]
  28. Yandle T. G., Richards A. M., Gilbert A., Fisher S., Holmes S., Espiner E. A. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993 Apr;76(4):832–838. doi: 10.1210/jcem.76.4.8473392. [DOI] [PubMed] [Google Scholar]
  29. Yoshimura M., Yasue H., Okumura K., Ogawa H., Jougasaki M., Mukoyama M., Nakao K., Imura H. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993 Feb;87(2):464–469. doi: 10.1161/01.cir.87.2.464. [DOI] [PubMed] [Google Scholar]
  30. Zweig M. H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561–577. [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES